Daklinza União Europeia - inglês - EMA (European Medicines Agency)

daklinza

bristol-myers squibb pharma eeig - daclatasvir dihydrochloride - hepatitis c, chronic - antivirals for systemic use - daklinza is indicated in combination with other medicinal products for the treatment of chronic hepatitis c virus (hcv) infection in adults (see sections 4.2, 4.4 and 5.1). for hcv genotype specific activity, see sections 4.4 and 5.1.,

MyDekla 60 Tablets 60 mg Tanzânia - inglês - Tanzania Medicinces & Medical Devices Authority

mydekla 60 tablets 60 mg

mylan laboratories limited, india - daclatasvir dihydrochloride - tablets - 60 mg

DACLAVIRDIN Film coated tablets 60 mg Tanzânia - inglês - Tanzania Medicinces & Medical Devices Authority

daclavirdin film coated tablets 60 mg

eva pharma for pharmaceuticals and medical appliances, egypt - daclatasvir dihydrochloride - film coated tablets - 60 mg

Daklinza 30mg tablets Reino Unido - inglês - MHRA (Medicines & Healthcare Products Regulatory Agency)

daklinza 30mg tablets

bristol-myers squibb pharmaceuticals ltd - daclatasvir dihydrochloride - tablet - 30mg

Daklinza 60mg tablets Reino Unido - inglês - MHRA (Medicines & Healthcare Products Regulatory Agency)

daklinza 60mg tablets

bristol-myers squibb pharmaceuticals ltd - daclatasvir dihydrochloride - tablet - 60mg

Daklinza 90mg tablets Reino Unido - inglês - MHRA (Medicines & Healthcare Products Regulatory Agency)

daklinza 90mg tablets

bristol-myers squibb pharmaceuticals ltd - daclatasvir dihydrochloride - tablet - 90mg

Daklinza 30 mg film-coated tablets União Europeia - inglês - myHealthbox

daklinza 30 mg film-coated tablets

bristol-myers squibb pharma eeig - daclatasvir dihydrochloride - film-coated tablet (tablet) - 30 mg - hepatitis c, chronic - direct-acting antiviral - indicated in combination with other medicinal products for the treatment of chronic hepatitis c virus (hcv) infection in adults

Daklinza 60 mg film-coated tablets União Europeia - inglês - myHealthbox

daklinza 60 mg film-coated tablets

bristol-myers squibb pharma eeig - daclatasvir dihydrochloride - film-coated tablet (tablet) - 60 mg - hepatitis c, chronic - direct-acting antiviral - indicated in combination with other medicinal products for the treatment of chronic hepatitis c virus (hcv) infection in adults